A challenge in developing effective CCK1R agonists for obesity treatment has been side effects since some have failed clinical trials, in addition to having minor or no additional benefits over acute dieting [93]. The gene discussed is CCKAR; the disease is obesity due to melanocortin 4 receptor deficiency.